So what are some of the paracrine actions of the adult stem cell secretome? 1. Antimicrobial
2. The switching of differentiated cells to back to progenitor cells 5 3. Wnt signaling to control stem cell niche organization 6 4. Building extracellular matrix (ECM) in most tissues 7 5. Modulation of the immune system 8 6. Wound healing 9 7. Regeneration of bone 10 8. Reversal of stress urinary incontinence 11 9. Regenerate functional intestine 12 10. Enhancing recovery from traumatic brain injury 13 11. Exosome release, a multipotent therapeutic 14 12. Proteasome release for clearing misfolded proteins 15 Development of therapeutics using the SRM of adult stem cell types leads us to a very different kind of therapeutic development than those offered by the development of small molecules or biologics.
Indeed, as in physics, where reductionism is being replaced with a systematic view of particles as an integral part of a collective, predictive, and coherent electrodynamic universe described by Mead, 16 biology and therapeutic it is that's moving is moving relative to other matter in the universe. And in biology, one molecule or one structure can only have meaning when viewed in relation to the other parts of the biological system. Indeed tissue models such as tensegrity exemplify the importance of the system where one part of the system is physically and chemically connected to the most other parts of the system, 21 and involved in many cellular functions including chromatin rearrangement, 22 ion channel flux control, 23 triggering the cell fate of stem cells, 24 and the tensional tuning of stem cells to the adjacent soft tissue physical state. 25 The systems biology approach is leading to the path of developing therapeutics that interact with the system, with reverse engineering of the many paracrine factors that stem cells release being instructive for the development of "systems therapeutics." 26 The development of SRM as a systems therapeutic is in contradistinction to the reductionist method of developing targeted small molecule drugs that interact with only one defined target. Further, because multiple types of stem cells are normally involved in tissue maintenance and repair, the SRM from different cell types is utilized to form a more potent version of the SRM. 26 Using a reductionist approach where just one of the molecules in SRM, instead of the total mix, has proven ineffective in a number of trials for therapeutic development and has led to the downfall of at least one public company. 27 The advantages of using the SRM for therapeutic development rather than the stem cells themselves are numerous. For example, stem cells may die or not home into the site of damaged tissue yielding an unknown dosing regimen, whereas the SRM can be dosed directly to the site of damage in a dosing regimen that can be controlled and defined in space and time. And the molecules can be optimally harvested under controlled laboratory conditions, producing the SRM from multiple cell types, to produce a set of state dependent molecules with the desired composition.
Stem cell therapy without the cells
Consider wound healing and cancer, their common mechanistic underpinnings of a disordered extracellular matrix (ECM) and described as "tumors: wounds that never heal," 28 are controlled significantly by SRM acting on the ECM. Then the observation that highly invasive fetal surgery produces no scarring, 29 rather a perfectly reformed ECM, and is not mediated by conditions of the womb such as hypoxia, but instead is mediated by an intrinsic primordial state of the fetal tissue, 29 and therefore presumably a primordial SRM state, leads us to believe that SRM, in a primordial state, may be developed as a therapeutic for indications where a deregulated ECM is evident. The system of molecules within this framework to build ECM in a more organized, scarless manner exists at a minimum of 2 levels where the SRM of mesenchymal stem cells establishes the instruction set to build the niche for the fibroblasts, and the SRM of the fibroblasts provides instructions to build and regulate the ECM niche with primordial, scar-less capabilities. Developing SRM-based therapeutics with the molecules providing instruction sets in a fetal, primordial manner may lead to a more perfect union of the ECM relevant to the many diseases and indications where a deregulated ECM is involved, such as cancer. (Fig. 1) 
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